Exin Therapeutics, Inc.
An AI discovery platform for neurotherapeutics targeting neural circuits across disorders.
About Exin Therapeutics, Inc.
We use AI and high-throughput mouse studies to discover therapeutics that modify neural activity in the brain. The initial focus is on epilepsies associated with autism and Parkinson’s disease with the potential to expand to any neurological disorder underlined by a dysfunction in neural activity. Our R&D is guided by AI models trained on high-density multimodal mouse data generated in-house.
We are 3 Oxford-trained neuroscientists supported by an experienced SAB from Harvard, Science Corp (ex-Neuralink), EPFL, Meta, and UCL.
In 1.5 months since landing in SF, we went from nothing to (1) opening and operating an animal lab in South SF, (2) obtaining a proof-of-concept in mice, (3) building a multimodal AI model that directs our screening approach and (4) submitting two provisional patents; all while utilizing less than 50% of our YC funding.
Products
A target discovery platform for neurotherapeutics that uses multimodal AI to predict drug candidate potential on multiple neural disorders simultaneously.
Information regarding the scientific approach and technology behind the AI discovery platform for neurotherapeutics.
Security and compliance
No security details published yet
Exin Therapeutics, Inc. hasn't published certifications or security practices that we could find. Ask their team for audit reports.
Is this your company?
Claim the profile to keep facts current, answer buyers and submit evidence for the next ranking review.
Claim Exin Therapeutics, Inc.